Reuters logo
BRIEF-Cellectar Biosciences announces new positive data from phase 1 clinical study of CLR 131 in multiple myeloma
September 29, 2016 / 12:52 PM / a year ago

BRIEF-Cellectar Biosciences announces new positive data from phase 1 clinical study of CLR 131 in multiple myeloma

Sept 29 (Reuters) - Cellectar Biosciences Inc :

* Cellectar Biosciences announces new positive data from phase 1 clinical study of CLR 131 in multiple myeloma

* Study’s data monitoring committee approved patient enrollment to third cohort, which will include a 33 percent dose increase

* All evaluable study participants have achieved stable disease and progression-free survival

* Patients in Cohort 2 did not experience proportional increase in adverse events Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below